|
|
|
| home > white papers > How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction - Temptime Corporation |
|
|
 WHITE PAPERS |
|
Temptime Corporation
|
|
How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction
|
|
The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION
Detailed results from the Phase III ADAURA trial showed AstraZeneca’s
Tagrisso (osimertinib) demonstrated a statistically significant and
clinically meaningful improvement in disease-free survival (DFS) in the
adjuvant treatment of patients with early-stage (IB, II and IIIA)
epidermal growth factor receptor-mutated (EGFRm) non-small cell lung
cancer (NSCLC) after complete tumour resection with curative intent.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
Clinical Operations in Oncology Trials West Coast
17-18 November 2020, Hilton San Francisco Airport Bayfront
Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >> |
|
|
|
